Sionna Therapeutics, Inc. (SION)
$4.69-4.29%Close
BUYCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $212M
- Beta
- 1.32
- P/E (TTM)
- -2.18
- Short % float
- 14.27%
- Days to cover
- 2.3
- SI change
- -4.3%
- 1W
- -3.30%
- 1M
- -40.25%
- vs SPY 1W
- -3.72%
- vs SPY 1M
- -42.32%
Industry peers
FMP comparable companies · ranked by market cap
- ABCLBUYAbCellera Biologics Inc.$3.9BCRISISQ -6$12.83+0.72%
- VERASELLVera Therapeutics, Inc.$2.2BCRISISQ 20$30.25-7.23%
- CLDXSELLCelldex Therapeutics, Inc.$2.0BCRISISQ 5$30.43-1.54%
- ZYMESELLZymeworks Inc.$2.0BBEARQ 12$26.53-1.78%
- IMNMSELLImmunome, Inc.$1.8BCRISISQ 18$19.09-2.05%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$11.88-2.24%
- XERSBUYXeris Biopharma Holdings, Inc.$1.7BBULLQ -1$10.11-0.19%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 37$26.25+2.18%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 12$17.92-1.31%
- ARDXSELLArdelyx, Inc.$805MBEARQ 1$3.26-1.52%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on SION?
- LOPJLB’s latest quantitative signal on Sionna Therapeutics, Inc. (SION) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is SION in?
- Sionna Therapeutics, Inc. (SION) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Sionna Therapeutics, Inc. (SION) do?
- Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-10…